We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-19.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2B
AUM Growth
+$181M
Cap. Flow
-$182M
Cap. Flow %
-9.13%
Top 10 Hldgs %
62.34%
Holding
416
New
102
Increased
87
Reduced
79
Closed
120

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$21.3M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$21.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
BIIB icon
Biogen
BIIB
+$9.79M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$8.84M

Top Sells

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$33.1M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.45M
3
MBLY
Mobileye N.V.
MBLY
+$7.26M
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$5.86M
5
ASXC
Asensus Surgical, Inc.
ASXC
+$5.01M

Sector Composition

Rank Sector Weight
1 Healthcare 11.94%
2 Consumer Staples 0.06%
3 Industrials 0.04%
4 Technology 0.04%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARCT icon
176
Arcturus Therapeutics
ARCT
$157M
$761K 0.04%
28,695
+4,766
+20% +$161K
IONS icon
177
PUT
Ionis Pharmaceuticals
IONS
$9.35B
$753K 0.04%
+186
New +$7.55K
CYTK icon
178
CALL
Cytokinetics
CYTK
$11B
$752K 0.04%
+1,066
New +$7.79K
OTIC
179
DELISTED
Otonomy, Inc.
OTIC
$746K 0.04%
+50,000
New +$785K
BNTC icon
180
Benitec Biopharma
BNTC
$394M
$739K 0.04%
1,655
-687
-29% -$505K
PRQR icon
181
ProQR Therapeutics
PRQR
$243M
$732K 0.04%
149,934
+110,063
+276% +$560K
VTVT icon
182
vTv Therapeutics
VTVT
$121M
$721K 0.04%
3,494
– –
BLCM
183
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$720K 0.04%
+7,702
New +$839K
ANTH
184
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$720K 0.04%
+24,865
New +$675K
EXEL icon
185
CALL
Exelixis
EXEL
$13.9B
$713K 0.04%
1,783
– –
ATRS
186
DELISTED
Antares Pharma, Inc.
ATRS
$675K 0.03%
775,212
+16,494
+2% +$16K
NTRA icon
187
Natera
NTRA
$37.5B
$659K 0.03%
69,272
-17,351
-20% -$147K
HZNP
188
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$646K 0.03%
+390
New +$6.82K
PTCT icon
189
CALL
PTC Therapeutics
PTCT
$6.37B
$644K 0.03%
1,000
+155
+18% +$2.69K
RLYP
190
CALL
DELISTED
RELYPSA INC COM
RLYP
$641K 0.03%
473
-557
-54% -$9.47K
OMER icon
191
CALL
Omeros
OMER
$709M
$637K 0.03%
415
-1,024
-71% -$12.4K
SLNO
192
DELISTED
Soleno Therapeutics
SLNO
$637K 0.03%
+7,074
New +$693K
BGMS
193
Bio Green Med Solution Inc
BGMS
$5.05M
$628K 0.03%
2
– –
SCPX
194
DELISTED
Scorpius Holdings, Inc.
SCPX
$626K 0.03%
+3
New +$1.47M
AKTX
195
Akari Therapeutics
AKTX
$15.2M
$606K 0.03%
+51
New +$529K
PGNX
196
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$603K 0.03%
1,384
+544
+65% +$2.42K
HALO icon
197
Halozyme
HALO
$9.72B
$568K 0.03%
+60,000
New +$565K
RLYP
198
PUT
DELISTED
RELYPSA INC COM
RLYP
$562K 0.03%
+415
New +$7.06K
SSKN
199
DELISTED
Strata Skin Sciences
SSKN
$542K 0.03%
11,462
-6,774
-37% -$351K
BPMC
200
DELISTED
Blueprint Medicines
BPMC
$535K 0.03%
+29,624
New +$514K
6 7
8
9 10

Similar funds

NA
Novus Advisors Greenville, South Carolina $44.7M AUM 18.41% 1-Year Est. Return
CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Sabby Management's Q1 2016 Portfolio in Review

As of Q1 2016, Sabby Management held 416 positions worth $2B, up 9.9% from $1.82B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sabby Management withdrew a net $182M in Q1 2016, closing 120 positions and reducing 79 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $33.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 10% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Sabby Management opened a new position in Amgen worth $21.5M.

  • Sabby Management's largest Q1 2016 buy was Amgen: 143,486 shares worth $21.5M.
  • Sabby Management added most to Northwest Biotherapeutics, Inc. Common stock in Q1 2016, an estimated $4.73M increase.
  • Sabby Management's biggest Q1 2016 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $7.45M.
  • Sabby Management fully exited iShares Russell 2000 ETF in Q1 2016, selling an estimated $33.1M.
  • Sabby Management's ten largest holdings make up 62% of its $2B portfolio in Q1 2016.
  • Sabby Management opened 102 new positions and closed 120 in Q1 2016.
  • Sabby Management's portfolio value rose 9.9% quarter-over-quarter to $2B.

Based on Sabby Management's 13F filing for Q1 2016, filed 13 May 2016.